Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2722)	5/10/2010 10:26:08 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ASTM is scheduled to report some results on its critical limb ischemia program at 1:00pm today.<g> They will hold a CC and webcast and Anthony J. Comerota, MD, FACS, FACC, director of the Jobst Vascular Center in Toledo, Ohio, will hold a Q&A session. Will see if the stock can get to close above the resistance at the $2 level It needs to do that before trying to close some of the DG of Jan16 above $2.24 <g> bigcharts.marketwatch.com The ACTAY is $0.50 <g> But the insiders have been buying recently: finance.yahoo.com It seems that with some good news the stock could get to the $5 level.<g> bigcharts.marketwatch.com I don't have any position on ASTM, but it seems to have some interesting research going on dilated cardiomyopathy with 40 patients enrolled at five sites across the U.S. ASTM plans to report 6-month interim data on all patients in the 4thQ. It also has a PII to explore a catheter-based delivery of tissue repair cells to treat DCM patients, which is currently enrolling patients. Its PIIb RESTORE-CLI is fully enrolled with 86 patients at 18 sites across the U.S to evaluate the use of TRCs in the treatment of patients suffering from critical limb ischemia. This is the one they will discuss at the CC today. Bernard